Tilray’s, Vape

Tilray’s Vape Push Emerges as Redecan Debut Reshapes the Stock Picture

11.12.2025 - 14:14:04

Tilray is rolling out a fresh product wave in the cannabis arena as its subsidiary Redecan prepares to launch a new premium vape line. On December 11, 2025, Redecan is set to introduce the Amped Live Resin Liquid Diamond vapes, timed to coincide with what the company views as peak season for vape products, which runs from December through February. The stock, trading at $8.26 per share, has been adjusted by a reverse split completed earlier in December.

Key facts at a glance:
- New Amped Live Resin Liquid Diamond vape series now available
- 1-for-10 reverse split effective December 1, reducing shares outstanding from about 1.16 billion to roughly 116 million
- TD Cowen price target: $10.00
- GuruFocus upgraded the stock from Strong Sell to Hold on December 4

Strategic timing aligned with market growth

The Amped line introduces 1-gram 510 cartridges that blend 80% Live Resin with 20% Liquid Diamonds. At launch, the flavors Space Age CK and Blueberry DNTS will be offered. Each cartridge features a TrueDraw Ceramic core designed to improve airflow and overall draw quality.

This timing is not incidental. Over the past six months, the Live Resin Vape category has expanded by 6.3%, and Tilray is targeting the peak season for vape products by releasing these offerings now.

Stock structural shift reshapes investors’ lens

Should investors sell immediately? Or is it worth buying Tilray?

The current trading level around $8.26 must be viewed through the lens of a broader corporate restructuring. Starting December 1, the company’s shares trade under a new CUSIP with the former tally of about 1.16 billion reduced to approximately 116 million shares following the 1-for-10 reverse split.

This consolidation aims to draw in institutional investors who previously shunned what was perceived as a penny-stock profile. Technically, the chart has been reset, meaning comparisons to price levels before December 2025 require adjustment by a factor of 10.

Analyst outlook and market reception

TD Cowen maintains a price target of $10.00, suggesting roughly 21% upside from current levels. On December 4, GuruFocus upgraded the stock from Strong Sell to Hold, acknowledging the improved balance sheet structure after the split.

The big question for investors is whether the new premium vape products can deliver the margin expansion needed to justify a $10 target within the reorganized equity base. The coming weeks will reveal how the market receives the vape offensive in the context of the company’s broader strategy.

Ad

Tilray Stock: Buy or Sell?! New Tilray Analysis from December 11 delivers the answer:

The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 11.

Tilray: Buy or sell? Read more here...

@ boerse-global.de